Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504084 | 0.83 | PIK3CD (0.70) | ATAD2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3574427 | 0.76 | ATAD2 (0.48) | ATAD2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2477606 | 0.75 | ALDH1A1 (0.50) | ATAD2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2072823 | 0.75 | ATAD2 (0.68) | ATAD2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL504077 | 0.73 | ATAD2 (0.49) | ATAD2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL302929 | 0.70 | ATAD2 (0.70) | ATAD2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL10070729 | 0.70 | ATAD2 (0.49) | ATAD2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL303321 | 0.69 | ATAD2 (1.00) | ATAD2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL10042015 | 0.68 | ALDH1A1 (0.46) | ATAD2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12415755 | 0.67 | ATAD2 (0.65) | ATAD2PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267498-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-10 | — | — | US | disclosed |
| US-20130267498-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-10 | — | — | US | disclosed |
| US-8399458-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399458-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399458-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120028965-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028965-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2094712-B1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2094712-B1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-10-12 | — | — | EP | disclosed |
| US-7838517-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838517-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838517-B2 | Compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090281082-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281082-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281082-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| EP-2094712-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008060597-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008060597-A2 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281082-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | ATAD2 2780/4885PIK3CD 99/4885PIK3CA 44/4885 |
| US-20120028965-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | ATAD2 2780/4885PIK3CD 99/4885PIK3CA 44/4885 |
| US-20130267498-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | ATAD2 2780/4885PIK3CD 99/4885PIK3CA 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.